Key Highlights
- Third-quarter Net Income was USD 59.1 million, or USD 0.30 per diluted share, against a net loss of USD 7.7 million, or USD 0.04 a share, in the same quarter of 2025.
- Total Revenue was only USD 0.3 million, down from USD 0.5 million, while a USD 67.3 million Cash Dividend from Genevant drove other income to USD 69.6 million.
- Cash, cash equivalents and marketable securities stood at USD 337.5 million on September 30, 2026, with no debt, before a USD 230 million share repurchase settled on October 5.
- Moderna may owe a further USD 1.3 billion, shared with Genevant, if a federal appeal ruling goes the right way; oral argument took place on November 5, 2026.
A Genevant Dividend Carries the Quarter
Arbutus Biopharma (NASDAQ:ABUS) filed its Quarterly Report for the period ended September 30, 2026 on November 10, 2026. Net income was USD 59.1 million, or USD 0.30 per diluted share, versus a loss of USD 7.7 million a year earlier. Operations did not drive the swing. Revenue was USD 0.3 million, operating expenses were USD 10.8 million, and the loss from operations was USD 10.5 million. The gain came from USD 69.6 million of other income, including a USD 67.3 million dividend from Genevant, a company in which Arbutus held about 16% of the common equity. The dividend distributed Genevant's Earnings from the Moderna settlement payment. Nine-month net income was USD 223.7 million, or USD 1.13 per diluted share.
Moderna Settlement Cash, Buyback and Spending
Under a March 2026 settlement, Moderna made a USD 950.0 million payment to Arbutus and Genevant in July 2026. Arbutus received USD 178.4 million as its share, which included reimbursement of litigation costs, and that lifted nine-month revenue to USD 180.4 million. The clinical-stage company, which is developing imdusiran and AB-101 for chronic hepatitis B, then ran a tender offer. On October 1, 2026 it accepted 46 million common shares at USD 5.00, a USD 230 million total, equal to about 23% of shares outstanding. General and administrative expense rose to USD 8.0 million from USD 3.0 million, mainly on one-time executive bonuses tied to the settlement, while Research and Development fell to USD 2.6 million from USD 5.8 million.
Appeal, Pfizer Suit and AB-101 Restart
The next catalyst is the Federal Circuit. A contingent USD 1.3 billion payment from Moderna, shared with Genevant and possibly subject to repayment, depends on a favorable ruling in a limited appeal, and a decision is forthcoming. Separately, the company is pursuing Patent suits against Pfizer and BioNTech, with a final pretrial conference scheduled for November 2027 and further international suits filed in July and November 2026. In October 2026 the FDA lifted its clinical hold on the AB-101 application. The 10-Q says substantial additional funds would be needed to keep developing the pipeline, and no trial date has been set for the Pfizer case.
Where Things Stand
The profit came from deal proceeds, not from the business. Arbutus Biopharma (NASDAQ:ABUS) earned USD 59.1 million because Genevant passed through USD 67.3 million, while revenue was USD 0.3 million and the operating loss was USD 10.5 million. The Balance Sheet is strong, with USD 337.5 million before the USD 230 million tender. Still, nearly all upside depends on legal outcomes. Watch the Federal Circuit decision on the USD 1.3 billion contingent payment, the Pfizer and BioNTech litigation timetable and any next steps on AB-101 and imdusiran.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...